XTRA:BAYNPharmaceuticals
Can Bayer (XTRA:BAYN) Still Trade At A Discount After A 75% Run?
Bayer stock has delivered a strong 74.5% return over the past year, yet broader valuation checks still suggest the shares screen as relatively cheap rather than fully pricing in that strength.
Over the last 12 months, Bayer has returned 74.5%. This puts recent share price momentum front and center for anyone assessing whether the current level is justified.
The new collaboration with Kairos Pharma around XOFIGO in metastatic prostate cancer can support longer term revenue expectations. At...